Randomized, open phase II study of immunization with the recombinant MAGE-3 protein [GSK 1572932A; MAGE-A3 ASCI] combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma.

Trial Profile

Randomized, open phase II study of immunization with the recombinant MAGE-3 protein [GSK 1572932A; MAGE-A3 ASCI] combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Zastumotide (Primary) ; AS02; AS15
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Dec 2015 Accrual to date is 2%, according to United Kingdom Clinical Research Network record.
    • 08 Dec 2015 Last checked against the United Kingdom Clinical Research Network.
    • 25 Jul 2013 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top